Description
There are significant differences in costs and effectiveness among the second-line treatment options for type 2 diabetes (T2DM). We aimed to evaluate the cost-effectiveness of the second-line anti-diabetic therapy in T2DM patients inadequately controlle...
| Date made available | 2020 |
|---|---|
| Publisher | Taylor & Francis |
Research output
- 1 Article
-
Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin
Chien, C. L., Chen, Y. C., Malone, D. C., Peng, Y. L. & Ko, Y., Oct 2 2020, In: Current Medical Research and Opinion. 36, 10, p. 1619-1626 8 p.Research output: Contribution to journal › Article › peer-review
6 Link opens in a new tab Scopus citations
Cite this
- DataSetCite